## Maarten Jacquemyn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8438547/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Nature Genetics, 2021, 53, 435-444.	21.4	162
2	Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing. Chemistry and Biology, 2015, 22, 107-116.	6.0	108
3	Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes. Nature Communications, 2018, 9, 502.	12.8	84
4	The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2017, 23, 2528-2541.	7.0	52
5	<scp>STK</scp> 38 kinase acts as <scp>XPO</scp> 1 gatekeeper regulating the nuclear export of autophagy proteins and other cargoes. EMBO Reports, 2019, 20, e48150.	4.5	34
6	<i>ATXN1</i> repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Communications, 2020, 2, fcaa064.	3.3	33
7	Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas. Science Translational Medicine, 2018, 10, .	12.4	30
8	Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma. EBioMedicine, 2015, 2, 1102-1113.	6.1	24
9	Loss of tRNA-modifying enzyme Elp3 activates a p53-dependent antitumor checkpoint in hematopoiesis. Journal of Experimental Medicine, 2021, 218, .	8.5	14
10	enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9. Molecular Therapy, 2021, 29, 208-224.	8.2	8
11	XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis. Blood Cancer Journal, 2021, 11, 27.	6.2	3
12	Selective Inhibitors of Nuclear Export (SINE) Compounds Suppress Both HIV Replication and AIDS Related Lymphoma. Blood, 2015, 126, 2751-2751.	1.4	1
13	Abstract 2442: XPO1 is selinexor prime target: validation by mutating cysteine 528 on both XPO1 alleles using CRISPR/Cas9 genome editing. , 2015, , .		0
14	Abstract LB-210: KPT-8602 is a second-generation XPO1 inhibitor with improvedin vivotolerability that demonstrates potent acute lymphoblastic leukemia activity. , 2016, , .		0